MARKET

CLYM

CLYM

Climb Bio
NASDAQ
13.54
-0.46
-3.29%
After Hours: 13.54 0 0.00% 19:34 08/10 EDT
OPEN
13.80
PREV CLOSE
14.00
HIGH
13.86
LOW
13.20
VOLUME
779.55K
TURNOVER
--
52 WEEK HIGH
14.53
52 WEEK LOW
1.540
MARKET CAP
777.69M
P/E (TTM)
-17.4530
1D
5D
1M
3M
1Y
5Y
1D
Guggenheim Reaffirms Their Buy Rating on Climb Bio (CLYM)
TipRanks · 13h ago
Weekly Report: what happened at CLYM last week (0803-0807)?
Weekly Report · 15h ago
RBC Capital Keeps Their Buy Rating on Climb Bio (CLYM)
TipRanks · 2d ago
Climb Bio price target raised to $25 from $17 at Truist
TipRanks · 3d ago
Climb Bio Price Target Raised to $25.00/Share From $17.00 by Truist Securities
Dow Jones · 3d ago
Climb Bio Is Maintained at Buy by Truist Securities
Dow Jones · 3d ago
Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25
Benzinga · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)
TipRanks · 4d ago
More
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.

Webull offers Climb Bio Inc stock information, including NASDAQ: CLYM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLYM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLYM stock methods without spending real money on the virtual paper trading platform.